Evofem Biosciences

Evofem Biosciences is a publicly traded company. Investment decisions, including capital allocation for R&D and commercial activities, are made by the board of directors and management team, led by CEO Saundra Pelletier. The company does not function as a family office; its operations are governed by SEC disclosure rules.

Evofem sources deal flow through licensing agreements, partnerships, and co-promotion deals within the biotech and pharmaceutical sectors. For example, it has partnered with AMAG Pharmaceuticals for co-promotion of Phexxi (per SEC filing, 2020). The firm's pipeline includes in-licensed candidates, though it does not disclose a proprietary sourcing method.

Evofem is a publicly traded biopharmaceutical company, not a family office. Its structure includes a board of directors, executive team, and shareholders. The firm's primary business is drug development and commercialization, with no disclosed wealth management or family-office services.

Evofem does not participate in fund commitments as an LP. As a public company, its capital is raised through equity offerings, debt, and revenue from product sales. It engages in direct licensing and partnership deals for its pipeline assets.

Evofem targets late-stage clinical and commercial-stage assets in women's health. Its lead product, Phexxi, is already FDA-approved and marketed. The company has sought to expand indications through phase 2 trials for HIV PrEP and a terminated chlamydia trial, but does not typically invest in early-stage research.

Evofem focuses exclusively on women's sexual and reproductive health. It avoids oncology, cardiovascular, neurology, and other therapeutic areas. The company's pipeline is centered on non-hormonal contraception, infection prevention, and reproductive health, as stated in its public filings.

Evofem is a publicly traded company with no disclosed wealth origin tied to a family office. Its capital comes from public investors, institutional holders, and retail shareholders. The firm's ownership structure includes mutual funds and index funds, but no controlling family or individual is named in its most recent proxy statement.